In a 48-week mid-stage trial involving people with obesity and type 2 diabetes, participants who remained on the highest-dose combination of Zepbound and eloralintide lost 23.3% of their weight, versus 14.8% with Zepbound and 11.1% with eloralintide alone. High discontinuation rates raised tolerabil